Concert Pharmaceuticals Appoints James V. Cassella as Chief Development Officer

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert’s product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.

“Jim has extensive experience leading the development of both novel compounds and reformulations of existing drugs for new indications,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “His broad experience base and proven leadership skills will be a great asset to Concert as we continue to advance and broaden our clinical pipeline. We are excited to have Jim join Concert at this important time in our further evolution as a product development company.”

Dr. Cassella brings to Concert more than 25 years of experience in drug development, including experience with product development, clinical trial design and execution, regulatory affairs, and product registration in the US and EU. Most recently, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. Prior to Alexza Pharmaceuticals, Dr. Cassella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Research and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability or efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer. For more information, please visit

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.
Justine Koenigsberg (Investors), 781-674-5284
The Yates Network
Kathryn Morris (Media), 845-635-9828
Posted in: Press

Comments are closed.